Should I buy Aurora Cannabis stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Aurora Cannabis's market performance for more than three years. Every month, hundreds of thousands of Canadians rely on us to interpret market trends and highlight the best investment opportunities available. Our reports are provided for informational purposes only and do not represent investment advice. As per our ethical guidelines, we have never been, and will never be, compensated by Aurora Cannabis.

What is Aurora Cannabis?

How much is Aurora Cannabis stock?

The price of Aurora Cannabis stock is rising this week. As of today, the current stock price stands at $4.69 CAD, showing a 1.11% gain over the past 24 hours, while the weekly change registers a decrease of 6.63%.

Aurora’s market capitalization totals $253.73 million, with a three-month average daily volume of approximately 1.79 million shares. The stock trades at a P/E ratio of 24.13 and does not currently offer a dividend yield. Its beta is notably high at 2.88, reflecting significant volatility.

Given these figures, investors should approach Aurora Cannabis with caution, balancing its recovery potential against the sector’s inherent risks.

Our full analysis on Aurora Cannabis stock

We have rigorously reviewed Aurora Cannabis Inc.’s latest financial results and dissected the stock’s trajectory over the past three years, employing a combination of financial indicators, technical charts, sector trends, and direct competitor analysis with our proprietary analytic algorithms. The result is a 360-degree view of a company that has endured volatility, but is demonstrating visible signs of operational and strategic resurgence. So, why might Aurora Cannabis stock once again become a strategic entry point into the evolving cannabis sector in 2025?

Recent Performance and Market Context

Aurora Cannabis (NASDAQ: ACB; TSX: ACB) has navigated a complex macro and sectoral backdrop headlined by regulatory evolution, shifting investor sentiment, and an increasingly global medical cannabis market. Over the trailing twelve months, the stock is down 36.26%, reflecting broad-based sector pressures and company-specific restructuring. However, the recent stabilization—an intraday increase of 1.11% to $4.69 per share, alongside a one-month drawdown of just 4.96% and a year-to-date loss trimmed to 10.39%—speaks to a company potentially emerging from its nadir.

• Q3 fiscal 2025 delivered 37% year-over-year revenue growth and a 316% YoY improvement in adjusted EBITDA, indicating progress in the company’s transformation plan.
• Aurora launched its first inhalable resin cartridges in the UK, furthering its push into higher-margin international medical markets.
• Facility upgrades in British Columbia highlight a commitment to efficiency and quality.

Against a backdrop of expanded legalization and global acceptance of medical cannabis, Canada’s sector is bracing for a period of renewed momentum. Aurora’s robust presence in the medical segment—contributing 77% of consolidated net revenue—positions it advantageously as regulatory clarity improves and patient demand accelerates, particularly in Europe and Oceania.

Technical Analysis

While the technical landscape has shown some contradictory signals, the undercurrents are shifting. The Relative Strength Index (RSI) stands at 42.34, a neutral zone that underscores neither overbought nor oversold conditions. The Moving Average Convergence Divergence (MACD) at -0.17 and the “death cross” (50-day MA at $4.70 below the 200-day MA at $4.80) have suggested a bearish tendency, but momentum appears to be flattening.

Key supports are crystallizing at $4.43, which marks a critical foundation tested during the latest market pullbacks. Resistance is seen at $4.86, and a break above could initiate a new bullish sequence, particularly if accompanied by volume expansion. The shorter-term 20-day and 5-day moving averages ($4.30 and $4.40, respectively) underscore the present consolidation zone, a classic precursor to inflection.

Short- and medium-term structure thus seems poised for a technical reversal contingent on sustained buying pressure—a typical catalyst for sharp upward moves in high-beta stocks like Aurora.

Fundamental Analysis

• Q3 net revenue surged to $88.2 million (+37% YoY), with global medical cannabis revenue up an impressive 51%.
• Adjusted EBITDA for Q3 stood at $23.1 million, a meaningful sequential and annual improvement.

The stock’s P/E ratio of 24.13, while indicating a return to profitability, is arguably attractive given Aurora’s dominant medical cannabis footprint, robust growth, and improving margin profile. The Price/Sales ratio at 1.10 and Price/Book at 0.62 further reinforce a narrative of discounted valuation versus sector peers, especially when factoring in the company’s IP portfolio, brand equity, and international partnerships.

Structurally, Aurora is consolidating its leadership in global medical cannabis—bolstered by innovation, with new resin-based and high-quality cannabinoid products, and by international expansion, notably in core European (Germany, UK, Poland) and Oceania markets. This diversity insulates revenue streams from single-market headwinds and provides optionality for sustained revenue compounding.

Volume and Liquidity

Trading volumes remain robust at 1.79 million shares daily—62% of the rolling 65-day average. This underpins a liquid market environment, facilitating both institutional and retail positioning. With a public float of 54.67 million shares and short interest of 9.05%, there is ample potential for dynamic price action, particularly if positive news flow or technical breakouts induce fresh buying and short covering.

Liquidity, anchored by a market cap of $253.73 million and cash reserves of $108.71 million, breeds investor confidence that the company can absorb intermittent volatility while executing on strategic pivots.

Catalysts and Positive Outlook

• Product Innovation: The recent UK launch of inhalable resin cartridges highlights the company’s R&D capabilities and commitment to differentiated offerings for patients in advanced medical markets.
• International Expansion: Strong momentum in Germany, Australia, the UK, and Poland is likely to amplify revenue diversity and insulation from North American market cycles. Ongoing regulatory progress in these geographies magnifies potential upside.
• Operational Efficiency: Post-pandemic rationalization and targeted investments (e.g., Pemberton facility upgrades) are set to translate into improved margin capture as volumes scale.
• Strategic Partnerships: The development agreement with Vectura Fertin Pharma on CBD products lays groundwork for higher-margin wellness and pharmaceutical innovations.
• ESG and Compliance: Aurora’s adherence to medical-grade manufacturing and compliance protocols position it favorably as global standards for cannabis intensify.

A favorable regulatory environment and societal acceptance—driven by aging populations, expanding insurance coverage for cannabinoid therapies, and consistently positive clinical outcomes—fuel optimism for sector-wide adoption and re-rating.

Investment Strategies

• Short-term: The consolidation near established support ($4.43) invites tactical entries for those seeking positioning ahead of a possible technical reversal or positive Q4/FY2025 earnings surprise. Volume and short interest dynamics set up fertile ground for short covering rallies.
• Medium-term: Accelerating growth in international medical sales, coupled with tangible operational efficiencies, suggest further margin improvement and incremental EBITDA scaling. Entry at current valuation levels could reap early-mover rewards as the market digests sequential financial progress.
• Long-term: For investors targeting secular growth, Aurora’s international diversification, product pipeline, and thought leadership in medical cannabis create attractive exposure to a multi-year global health trend. Early investment at this stage could capture proportionately larger gains as sector tailwinds and Aurora’s execution gain force.

Is It the Right Time to Buy Aurora Cannabis?

In summation, Aurora Cannabis exhibits a convergence of technical stabilization, improving fundamentals, and formidable strategic positioning which, collectively, seem to represent an excellent opportunity for renewed investor interest. The company’s focused resurgence in medical cannabis—underscored by double-digit revenue growth, EBITDA inflection, and international expansion—differentiates it as a prime candidate to benefit from the next upcycle in the global cannabis sector.

While volatility and sector risk factors remain, the balance of evidence distinctly tilts toward a stock entering a new bullish phase. The current valuation, substantial liquidity, fresh product launches, and exposure to high-growth international markets form a compelling narrative.

For investors seeking a high-conviction, turnaround opportunity in Canadian healthcare innovation, Aurora Cannabis stands out as a differentiated play positioned to outperform as macro and sectoral alignment accelerate through 2025. The current setup offers significant upside potential for those ready to anticipate the next wave of growth in global medical cannabis.

In a sector poised for evolution, Aurora Cannabis may well be at the forefront—meriting close consideration for a strategic spot in forward-looking portfolios.

How to buy Aurora Cannabis stock in Canada?

Buying Aurora Cannabis shares online through a regulated broker is a simple and secure process, well-suited to Canadian investors. You can choose between two popular methods: buying shares outright (known as spot buying) or trading Contracts for Difference (CFDs) that track the share price. Each option offers distinct benefits in terms of ownership and trading strategies. For newcomers and seasoned investors alike, online platforms provide transparency, strong security, and accessible tools to get started. For a complete overview of competitive brokers in Canada who offer access to Aurora Cannabis stock, check out our detailed comparison further down this page.

Spot buying

Spot buying means purchasing real Aurora Cannabis shares in your own name via a regulated brokerage account. This gives you direct ownership, with the right to hold for the long term or sell when you choose. With most Canadian brokers, you’ll pay a fixed commission per order—typically ranging from $5 to $10 CAD per trade.

Important information

Example: If the Aurora Cannabis share price is $4.69 CAD, a $1,000 investment (minus a typical $5 commission) enables you to acquire around 211 shares.
- Gain scenario: If the share price increases by 10%, your shares would be worth $1,100.
Result: That’s a gross gain of $100, or +10% on your initial investment (before taxes and other potential fees).

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on Aurora Cannabis’s share price movements without owning actual shares. CFDs are popular for their flexibility and the ability to use leverage, but they involve unique risks. The broker charges a spread (difference between buy and sell price) and, if you hold positions overnight, daily financing costs.

Important information

Example: You open a CFD position on Aurora Cannabis with $1,000 and elect 5x leverage. This ramps up your market exposure to $5,000, amplifying both gains and losses.
- Gain scenario: If Aurora Cannabis’s stock rises by 8%, your position gains 8% × 5 = 40%.
Result: You would pocket a $400 gain on your $1,000 investment (not counting spreads or overnight fees).

Final advice

Before investing, it’s vital to carefully review each broker’s fees, trading conditions, and platform features, as costs can vary significantly. Your preferred approach—spot buying for straightforward ownership, or CFDs for leveraged short-term trading—should fit your individual goals and risk appetite. To make an informed choice, consult our broker comparison chart further below on this page.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying Aurora Cannabis stock

The latest news about Aurora Cannabis

Aurora Cannabis reports strong year-over-year Q3 revenue growth, led by global medical cannabis sales. In its latest quarterly results for the period ending December 31, 2024, Aurora Cannabis posted net revenues of $88.2 million, reflecting a robust 37% growth compared to the same period last year. Of particular note for Canadian investors, medical cannabis spearheaded this performance, accounting for 77% of consolidated net revenue with a remarkable 51% year-over-year increase globally. This underscores Aurora’s continuing leadership in the medical cannabis segment, a critical differentiator in the highly competitive Canadian cannabis market, and points to sustained demand in both domestic and international channels.

Aurora completes $3 million upgrade to its British Columbia manufacturing facility, strengthening its Canadian production base. In April 2025, Aurora finalized substantial investments aimed at modernizing and expanding its manufacturing capabilities in Pemberton, BC. This initiative, valued at $3 million, is expected to boost production efficiency and support the introduction of innovative cannabis products tailored to medical and consumer needs. Such improvements directly benefit the company’s Canadian operations, ensuring Aurora remains well-positioned to deliver high-quality products, meet evolving regulatory standards, and respond quickly to market opportunities in Canada and abroad.

Collaboration with Vectura Fertin Pharma accelerates CBD product development, enhancing Aurora’s innovation pipeline. Aurora has entered a commercial partnership with Vectura Fertin Pharma to co-develop advanced CBD formulations. This strategic move enables Aurora to leverage cutting-edge drug delivery technologies and reinforces its commitment to product differentiation, primarily targeting the medical segment. For the Canadian market, these innovations not only enhance patient treatment options but also strengthen Aurora’s standing amid tightening competition and shifting regulatory expectations.

International expansion drives revenue diversification, with increased sales in key markets like Australia, Germany, Poland, and the UK. Building on its reputation as a global leader in medical cannabis, Aurora has reported significant progress in expanding its international footprint. Recent quarters have seen increased shipments to medical markets in Australia and Europe, as well as the launch of new product formats such as inhalable resin cartridges for UK patients. These efforts diversify revenue streams, mitigate risks associated with the Canadian market’s maturation, and position Aurora favorably in the rapidly growing international medical cannabis landscape, an important consideration for Canadian shareholders seeking exposure to global growth trends.

Financial discipline results in significant EBITDA improvement, indicating a positive momentum in operational efficiency. Aurora’s adjusted EBITDA soared 316% year-over-year in Q3 fiscal 2025, reaching $23.1 million—its strongest quarter to date. This positive trend reflects successful cost controls, operational streamlining, and revenue growth in core medical cannabis markets. Despite lingering concerns regarding free cash flow, this marked improvement demonstrates Aurora’s continued progress on its turnaround strategy. Canadian investors will find reassurance in this operational momentum, as it signals progress toward long-term profitability and financial sustainability in a challenging sector.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.